2026-03-15T17:00:12Z https://dmu.repo.nii.ac.jp/oai

oai:dmu.repo.nii.ac.jp:00000644 2023-06-20T16:12:19Z 81:45

チョウキ ホルモン ホジュウ リョウホウ (hormone replacement therapy:HRT) シコウチュウ ノ コツリョウ ゲンショウ ヘイケイゴ ジョセイ ノ コツミツド ニ タイスル ビスフォスフォネート セイザイ ヘイヨウ コウカ ト チョウキ HRT シコウチュウ ノ コウレイ ジョセイ 二オケル コツミツド ノ ヘンカ ニ カンスル リンショウテキ ケンキュウ 長期ホルモン補充療法(hormone replacement therapy:HRT)施行中の骨量減少閉経後女性の骨密度に対するビスフォスフォネート製剤併用効果と長期HRT施行中の高齢女性における骨密度の変化に関する臨床的研究 The Additive Effect of Risedronate, a Bisphosphonate, on the Bone Mineral Density (BMD) in Osteopenic Postmenopausal Women Treated with Long-term Hormone Replacement Therapy (HRT) and the Long-term HRT Effect on the BMD in Older Postmenopausal Women 濱田, 佳伸 ハマダ, ヨシノブ Hamada, Yoshinobu 骨量減少 ホルモン補充療法 リセドロネート ビスフォスフォネート 骨代謝マーカー 近年,強力な骨吸収抑制作用を持つビスフォスフォネート製剤が骨粗鬆症の治療に使用されている.長期間(3年以上,平均±SE:6.0±1.2年)のホルモン補充療法(hormone replacement therapy:HRT)を施行中の骨量減少患者を対象にリセドロネート2.5mg/日を投与し[Risedronate (Ris)+HRT群, n=11],投与前と投与後42ヶ月間, 6ヶ月に1回,骨密度(bone mineral density:BMD)を測定した.また,長期HRT施行中でBMDが正常の比較的高齢女性(HRT単独群,平均59.7±1.6歳, n=13),およびHRTを行っていないがBMDが正常の高齢女性(無治療群,平均57.3±1.6歳, n=20)の42ヶ月にわたるBMDの変化を比較した. Ris+HRT群のBMDは投与開始後全期間を通じて持続的に有意に増加した. HRT単独群のBMDは全期間を通じて有意な変化を認めなかったが,無治療群のBMDは,観察開始後18～42ヶ月で有意に低下した.これらより長期HRT施行中の骨量減少患者に対するリセドロネートのBMD増加効果を明らかにした.また,高齢女性における長期HRT (半量投与を含む)のBMD維持効果が判明した. Hormone replacement therapy (HRT) improves the bone mineral density (BMD) of postmenopausal patients with osteoporosis or osteopenia. However, treatment with long-term HRT for more than 3 years diminishes an increasing effect on BMD but prevents further bone loss. The present studies were designed to investigate the effects of rise-dronate (Ris), a pyridinyl bisphosphonate, on BMD in osteopenic postmenopausal women with a mean age of 50.3±2.9 years who had received long-term HRT for more than 3 years and of long-term HRT on BMD in relatively older women with normal BMD. 2.5mg daily of risedronate was administered for 42 months to 11 osteopenic postmenopausal women treated with long-term HRT, the duration of which was 6.0±1.2 years (Ris+HRT group). BMD and biochemical bone markers were determined at the initiation of observation and thereafter every 6 months for 42 months in the above-mentioned 11 osteopenic women, 13 relatively older women with a mean age of 59.2±1.6 years who had received long-term HRT for an average of 6.1±0.7 years (HRT group) and other 20 relatively older women with a mean age of 57.3±1.6 years who had never received HRT (non-HRT group), The BMD in the women of both older groups were normal when the study was initiated. Percent changes of BMD in the Ris+HRT group were significantly increased all through the 42 months. Those in the HRT group did not show any significant changes for 42 months and those in the non-HRT group were significantly decreased between 18 and 42 months after the initiation of observation. These results indicate that Ris significantly increases the BMD in those who had received long-term HRT and treatment with long-term HRT including half a dose of HRT is effective for maintaining the BMD in older postmenopausal women. 原著 Original journal article 2008-03-01 application/pdf Dokkyo journal of medical sciences 1 35 27 36 AA00629581 03855023 https://dmu.repo.nii.ac.jp/record/644/files/KJ00005058748.pdf https://dmu.repo.nii.ac.jp/records/644 jpn